N-α-(9-Fluorenylmethoxycarbonyl)-β-cyclopentyl-L-alanine
Need Assistance?
  • US & Canada:
    +
  • UK: +

N-α-(9-Fluorenylmethoxycarbonyl)-β-cyclopentyl-L-alanine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Fmoc-Amino Acids
Catalog number
BAT-005512
CAS number
371770-32-0
Molecular Formula
C23H25NO4
Molecular Weight
379.46
N-α-(9-Fluorenylmethoxycarbonyl)-β-cyclopentyl-L-alanine
IUPAC Name
(2S)-3-cyclopentyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
Synonyms
Fmoc-Ala(cPen)-OH; Fmoc-Ala(Cyclopentyl)-OH; Fmoc-L-cyclopentylalanine; Fmoc-(S)-3-Cyclopentylalanine; (2S)-3-cyclopentyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
Appearance
White to off-white powder
Purity
≥ 99.5% (Chiral HPLC)
Density
1.234±0.060 g/cm3
Boiling Point
598.0±33.0 °C
Storage
Store at 2-8 °C
InChI
InChI=1S/C23H25NO4/c25-22(26)21(13-15-7-1-2-8-15)24-23(27)28-14-20-18-11-5-3-9-16(18)17-10-4-6-12-19(17)20/h3-6,9-12,15,20-21H,1-2,7-8,13-14H2,(H,24,27)(H,25,26)/t21-/m0/s1
InChI Key
NVZVRXJTMCMDNR-NRFANRHFSA-N
Canonical SMILES
C1CCC(C1)CC(C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24

N-α-(9-Fluorenylmethoxycarbonyl)-β-cyclopentyl-L-alanine (Fmoc-β-cyclopentyl-D-alanine) is a specialized derivative integral to peptide synthesis and diverse biochemical applications. Let's explore the key applications of N-α-(9-Fluorenylmethoxycarbonyl)-β-cyclopentyl-L-alanine with a twist of high perplexity and burstiness:

Peptide Synthesis: Delving into the realm of complex peptides and proteins, Fmoc-β-cyclopentyl-D-alanine emerges as a pivotal player. With its Fmoc group standing as a guardian, allowing precision in the gradual addition of amino acids, researchers embark on a journey of crafting peptides with bespoke sequences—a vital endeavor in both research and therapeutic arenas.

Drug Development: The saga of innovation unfolds as this compound finds itself at the core of designing novel peptide-based drugs. Integrating Fmoc-β-cyclopentyl-D-alanine into peptide chains births molecules that boast enhanced stability and bioavailability, charting a new course in therapy development. This advancement holds particular significance in the crusade against conditions like cancer and metabolic disorders, ushering in a new era of peptide therapeutics.

Biophysical Studies: Venturing into the intricacies of biophysics, Fmoc-β-cyclopentyl-D-alanine emerges as a key to unlocking the structural and functional mysteries of peptides and proteins. Researchers wield this modified amino acid as a tool to introduce specific conformational restrictions, paving the way for in-depth exploration of protein folding and interactions. These revelations are pivotal in unraveling the dance of protein dynamics and crafting resilient protein formulations.

Immunology Research: Within the realm of immunology, Fmoc-β-cyclopentyl-D-alanine finds its place in the realm of synthetic antigens and epitopes. This symbiosis aids in fostering the growth of vaccines and the dissection of immune responses. Tailoring modified peptides to heighten antigen presentation and evoke potent immune reactions forms the cornerstone of vaccine efficacy and immunotherapeutic strategies, shaping the future of immunology research.

1. A 'conovenomic' analysis of the milked venom from the mollusk-hunting cone snail Conus textile--the pharmacological importance of post-translational modifications
Zachary L Bergeron, et al. Peptides. 2013 Nov;49:145-58. doi: 10.1016/j.peptides.2013.09.004. Epub 2013 Sep 18.
Cone snail venoms provide a largely untapped source of novel peptide drug leads. To enhance the discovery phase, a detailed comparative proteomic analysis was undertaken on milked venom from the mollusk-hunting cone snail, Conus textile, from three different geographic locations (Hawai'i, American Samoa and Australia's Great Barrier Reef). A novel milked venom conopeptide rich in post-translational modifications was discovered, characterized and named α-conotoxin TxIC. We assign this conopeptide to the 4/7 α-conotoxin family based on the peptide's sequence homology and cDNA pre-propeptide alignment. Pharmacologically, α-conotoxin TxIC demonstrates minimal activity on human acetylcholine receptor models (100 μM, <5% inhibition), compared to its high paralytic potency in invertebrates, PD50 = 34.2 nMol kg(-1). The non-post-translationally modified form, [Pro](2,8)[Glu](16)α-conotoxin TxIC, demonstrates differential selectivity for the α3β2 isoform of the nicotinic acetylcholine receptor with maximal inhibition of 96% and an observed IC50 of 5.4 ± 0.5 μM. Interestingly its comparative PD50 (3.6 μMol kg(-1)) in invertebrates was ~100 fold more than that of the native peptide. Differentiating α-conotoxin TxIC from other α-conotoxins is the high degree of post-translational modification (44% of residues). This includes the incorporation of γ-carboxyglutamic acid, two moieties of 4-trans hydroxyproline, two disulfide bond linkages, and C-terminal amidation. These findings expand upon the known chemical diversity of α-conotoxins and illustrate a potential driver of toxin phyla-selectivity within Conus.
2. Preparation of protected peptidyl thioester intermediates for native chemical ligation by Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) chemistry: considerations of side-chain and backbone anchoring strategies, and compatible protection for N-terminal cysteine
C M Gross, D Lelièvre, C K Woodward, G Barany J Pept Res. 2005 Mar;65(3):395-410. doi: 10.1111/j.1399-3011.2005.00241.x.
Native chemical ligation has proven to be a powerful method for the synthesis of small proteins and the semisynthesis of larger ones. The essential synthetic intermediates, which are C-terminal peptide thioesters, cannot survive the repetitive piperidine deprotection steps of N(alpha)-9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Therefore, peptide scientists who prefer to not use N(alpha)-t-butyloxycarbonyl (Boc) chemistry need to adopt more esoteric strategies and tactics in order to integrate ligation approaches with Fmoc chemistry. In the present work, side-chain and backbone anchoring strategies have been used to prepare the required suitably (partially) protected and/or activated peptide intermediates spanning the length of bovine pancreatic trypsin inhibitor (BPTI). Three separate strategies for managing the critical N-terminal cysteine residue have been developed: (i) incorporation of N(alpha)-9-fluorenylmethoxycarbonyl-S-(N-methyl-N-phenylcarbamoyl)sulfenylcysteine [Fmoc-Cys(Snm)-OH], allowing creation of an otherwise fully protected resin-bound intermediate with N-terminal free Cys; (ii) incorporation of N(alpha)-9-fluorenylmethoxycarbonyl-S-triphenylmethylcysteine [Fmoc-Cys(Trt)-OH], generating a stable Fmoc-Cys(H)-peptide upon acidolytic cleavage; and (iii) incorporation of N(alpha)-t-butyloxycarbonyl-S-fluorenylmethylcysteine [Boc-Cys(Fm)-OH], generating a stable H-Cys(Fm)-peptide upon cleavage. In separate stages of these strategies, thioesters are established at the C-termini by selective deprotection and coupling steps carried out while peptides remain bound to the supports. Pilot native chemical ligations were pursued directly on-resin, as well as in solution after cleavage/purification.
3. Syntheses of T(N) building blocks Nalpha-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosyl)-L-serine/L-threonine pentafluorophenyl esters: comparison of protocols and elucidation of side reactions
Mian Liu, Victor G Young Jr, Sachin Lohani, David Live, George Barany Carbohydr Res. 2005 May 23;340(7):1273-85. doi: 10.1016/j.carres.2005.02.029.
T(N) antigen building blocks Nalpha-(9-fluorenylmethoxycarbonyl)-O-(3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosyl)-L-serine/L-threonine pentafluorophenyl ester [Fmoc-L-Ser/L-Thr(Ac3-alpha-D-GalN3)-OPfp, 13/14] have been synthesized by two different routes, which have been compared. Overall isolated yields [three or four chemical steps, and minimal intermediary purification steps] of enantiopure 13 and 14 were 5-18% and 6-10%, respectively, based on 3,4,6-tri-O-acetyl-D-galactal (1). A byproduct of the initial azidonitration reaction of the synthetic sequence, that is, N-acetyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosylamine (5), has been characterized by X-ray crystallography, and shown by 1H NMR spectroscopy to form complexes with lithium bromide, lithium iodide, or sodium iodide in acetonitrile-d3. Intermediates 3,4,6-tri-O-acetyl-2-azido-2-deoxy-alpha-D-galactopyranosyl bromide (6) and 3,4,6-tri-O-acetyl-2-azido-2-deoxy-beta-D-galactopyranosyl chloride (7) were used to glycosylate Nalpha-(9-fluorenylmethoxycarbonyl)-L-serine/L-threonine pentafluorophenyl esters [Fmoc-L-Ser/L-Thr-OPfp, 11/12]. Previously undescribed low-level dehydration side reactions were observed at this stage; the unwanted byproducts were easily removed by column chromatography.
Online Inquiry
Inquiry Basket